Hybrid cytokines
US6171824A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 8, 1993 |
| Grant date | Jan 9, 2001 |
| Priority date | — |
| Expiry date | Nov 8, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Therapeutic hybrid cytokines, having a size ranging from about 10 to about 30 kDa, comprise portions of cytokines: leukemia inhibitory factor (LIF), granulocyte-colony stimulating factor (G-CSF), interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin-M (OSM), and ciliaryneurotrophic factor (CNTF). Hybrid cytokines comprise three or four .alpha.-helical sequences selected from .alpha.-helical sequences of IL-6, G-CSF, LIF, IL-11, CNTF and OSM and linking sequences of 5-40 amino acids in length, selected from the linking sequences of IL-6, G-CSF, LIF, IL-11, CNTF and OSM or other, desirable linking sequences. In the hybrid cytokines, at least one .alpha.-helical sequence is derived from a different cytokine than at least one other .alpha.-helical sequence; or, at least one linking sequence of a cytokine differentiates the hybrid cytokine from a corresponding cytokine. In hybrid cytokines having three .alpha.-helical sequences selected from the group of cytokines listed, a possible fourth sequence may not correspond to any .alpha.-helical sequence in any of the cytokines. Hybrid cytokines, radically different from any corresponding cytokines, have unexpected advantages in selective …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.